About the Authors

Mark D. Huffman


Affiliation Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States of America

Competing Interests

I have read the journal's policy and have the following conflicts: I receive grant support from the World Heart Federation as senior program advisor for its Emerging Leaders program, which has received funding from AstraZeneca in the past and is current supported by Boehringer Ingelheim and Bupa, which are not manufacturers of fixed-dose combination therapy. I have led the 2012 and 2014 applications to the World Health Organization’s Model List of Essential Medicines for inclusion of fixed-dose combination therapy for the secondary prevention of cardiovascular diseases. I am also the senior author of the 2014 Cochrane systematic review on fixed-dose combination therapy and coordinating editor of the Cochrane Heart Group US Satellite at Northwestern. I also receive grant support from the National Heart, Lung, and Blood Institute for heart attack quality improvement clinical trial and from the National Cancer Institute for a smoking cessation clinical trial. I have also received travel support from the Cochrane Collaboration (Heart Group), American Heart Association, and World Heart Federation in the past two years.

Author Contributions

Wrote the first draft of the manuscript: MDH. Contributed to the writing of the manuscript: MDH. Agree with the manuscript’s results and conclusions: MDH. The author has read, and confirms that he meets, ICMJE criteria for authorship.